Table 3.
Distribution of overall comorbid scores by patient characteristics and tumor site
| Characteristic | None | Mild | Moderate | Severe | P valuea |
|---|---|---|---|---|---|
| Tumor Site | |||||
| Oral Cavity | 26 (30.2%) | 31 (36.1%) | 23 (26.7%) | 6 (7%) | |
| Oropharynx | 18 (17.5%) | 53 (51.5%) | 24 (23.3%) | 8 (7.8%) | P = .110 |
| Larynx | 9 (9.8%) | 37 (40.2%) | 34 (37%) | 12 (13%) | P = .005 |
| Smoking | |||||
| All Sites | |||||
| Never | 18 (40.9%) | 14 (31.8%) | 11 (25%) | 1 (2.3%) | |
| Past | 17 (13.1%) | 67 (51.5%) | 38 (29.2%) | 8 (6.2%) | P = .001 |
| Current | 19 (16.8%) | 44 (38.9%) | 32 (28.3%) | 18(15.9%) | P = .001 |
| Larynx | |||||
| Never | 1 (33.3%) | 1 (33.3%) | 1 (33.3%) | 0 (0%) | |
| Past | 2 (4.2%) | 23 (47.9%) | 18 (37.5%) | 5 (10.4%) | P = .209 |
| Current | 6 (14.6%) | 13 (31.7%) | 15 (36.6%) | 7 (17.1%) | P = .768 |
| Oropharynx | |||||
| Never | 7 (41.2%) | 7 (41.2%) | 3 (17.7%) | 0 (0%) | |
| Past | 8 (18.6%) | 23 (53.5%) | 10 (23.3%) | 2 (4.7%) | P = .282 |
| Current | 3 (7%) | 23 (53.5%) | 11 (25.6%) | 6 (14%) | P = .009 |
| Oral Cavity | |||||
| Never | 10 (41.7%) | 6 (25%) | 7 (29.2%) | 1 (4.2%) | |
| Past | 6 (16.7%) | 19 (52.8%) | 10 (27.8%) | 1 (2.8%) | P = .105 |
| Current | 9 (36%) | 6 (24%) | 6 (24%) | 4 (16%) | P = .591 |
| Age (years) | |||||
| All Sites | |||||
| <60 | 36 (29%) | 46 (37.1%) | 30 (24.2%) | 12 (9.7%) | |
| 60+ | 19 (11.6%) | 79 (48.2%) | 51 (31.1%) | 15 (9.2%) | P = .002 |
| Larynx | |||||
| <60 | 6 (15.4%) | 14 (35.9%) | 13 (33.3%) | 6 (15.4%) | |
| 60+ | 3 (5.7%) | 23 (43.4%) | 21 (39.6%) | 6 (11.3%) | P = .222 |
| Oropharynx | |||||
| <60 | 14 (29.8%) | 20 (42.6%) | 10 (21.3%) | 3 (6.4%) | |
| 60+ | 4 (7.1%) | 33 (58.9%) | 14 (25.0%) | 5 (8.9%) | P = .027 |
| Oral Cavity | |||||
| <60 | 15 (41.7%) | 12 (33.3%) | 7 (19.4%) | 2 (5.6%) | |
| 60+ | 11 (22.0%) | 19 (38.0%) | 16 (32.0%) | 4 (8.0%) | P = .239 |
| HPV Status | |||||
| All Sites | |||||
| HPV16 − | 19 (15.7%) | 51 (42.2%) | 39 (32.2%) | 12 (9.9%) | |
| HPV16 + | 8 (26.7%) | 15 (50.0%) | 6 (20.0%) | 1 (3.3%) | P = .251 |
| Larynx | |||||
| HPV16 − | 4 (9.5%) | 15 (35.7%) | 19 (45.2%) | 4 (9.5%) | |
| HPV16 + | 1 (50.0%) | 0 (0.0%) | 1 (50.0%) | 0 (0.0%) | P = .371 |
| Oropharynx | |||||
| HPV16 − | 2 (6.5%) | 18 (58.1%) | 7 (22.6%) | 4 (12.9%) | |
| HPV16 + | 7 (28.0%) | 12 (48.0%) | 5 (20.0%) | 1 (4.0%) | P = .159 |
| Oral Cavity | |||||
| HPV16 − | 13 (27.1%) | 18 (37.5%) | 13 (27.1%) | 4 (8.3%) | |
| HPV16 + | 0 (0.0%) | 2 (100.0%) | 0 (0.0%) | 0 (0.0%) | P = .576 |
a
P value by chi-square or Fisher’s exact test comparing comorbid scores between rows using the first row as the reference group. Row percentages shown.